一种基于多分类多等级结局的广义I/II期剂量优化试验设计
该研究提出一种I/II期剂量优化设计,同时考虑多分类毒性结局与多等级疗效结局,按预设临床意义权重矩阵换算为拟连续概率,借鉴键盘设计以毒性概率区间筛除过毒剂量,并通过比较相邻剂量后验剂量合意度进行升降阶决策,可在非单调递增剂量-疗效关系下识别最优生物剂量。
要点
- 同时处理多分类毒性与多等级疗效,按预设权重矩阵转换为拟连续概率
- 借鉴键盘设计用毒性概率区间筛除过毒剂量
- 依据相邻剂量合意度后验分布自适应升降阶,适用于非单调剂量-疗效关系
核心结论
- 作者提出一种同时考虑多分类毒性和多等级疗效的I/II期设计,可在非单调递增剂量-疗效关系下更准确识别最优生物剂量。
- 多场景数值模拟的多项操作特征基准比较结果支持该设计在保证稳健性的同时整体表现领先。
研究设计与样本
- 该研究为方法学论文,提出一种I/II期剂量优化试验设计,并通过多场景数值模拟评估其性能并与已有设计比较。
主要发现
- 该设计按预设临床意义权重矩阵将多分类毒性及多等级疗效结局转换为拟连续概率。
- 该设计借鉴键盘设计,用毒性概率区间筛除过毒剂量。
- 该设计通过比较当前剂量相邻水平的剂量合意度(效用)后验分布,自适应作出升阶或降阶决策。
- 多场景数值模拟从安全性、准确性和可靠性方面评估该设计,并与已有多种设计进行比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pursuing accurate observations and rational assumptions always drives advances in clinical trial design. In recent years, more trials have begun to collect multi-graded outcomes for more informative analyses. At the same time, assumptions other than the traditional monotonicity relationship have been considered in the dose-efficacy curve to be more realistic. Inspired by these two trends, we propose a phase I/II design that simultaneously considers multi-categorical toxicity and efficacy with multi-graded outcomes, measured as quasi-continuous probability based on prespecified weight matrices of clinical significance. Following keyboard design, our approach aims to screen out overly toxic doses by the toxicity probability intervals and adaptively makes dose escalation or de-escalation decisions by comparing the posterior distributions of dose desirability (utility) among the adjacent levels of the current dose. It helps to more accurately identify the OBD in a non-monotonically increasing dose-efficacy relationship. We also comprehensively present the safety, accuracy and reliability performance through numerical simulations in multiple scenarios and compare the results with several already available designs. The benchmarking results of multiple operating characteristics convincingly support that our design leads in overall performance while ensuring robustness.
引用
- Yan Y, Lin R, Guan T, et al. A Generalized Phase I/II Dose Optimization Trial Design With Multi-Categorical and Multi-Graded Outcomes. Stat Med. 2025. PMID: 40213898. doi:10.1002/sim.70049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。